Novo Biosciences achieves major milestones in moving trodusquemine into clinical trials

(Novo Biosciences) Novo Biosciences Inc., has achieved several major milestones in its mission of bringing its breakthrough drug candidate, trodusquemine (aka MSI-1436), to market as a potential regenerative medicine treatment for heart disease and Duchenne muscular dystrophy (DMD). Trodusquemine is a repurposed drug candidate that has already been shown to be well tolerated by patients.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news